| Chimeric antigen receptor T-cell therapy - assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1.1K |
| Next generation of immune checkpoint therapy in cancer: new developments and challenges | Journal of Hematology and Oncology | 2018 | 375 |
| Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet | Leukemia | 2018 | 263 |
| Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance | New England Journal of Medicine | 2018 | 216 |
| Systemic immunoglobulin light chain amyloidosis | Nature Reviews Disease Primers | 2018 | 207 |
| Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia | Cell | 2018 | 197 |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma | Blood | 2018 | 196 |
| Post-Transplantation Lymphoproliferative Disorders in Adults | New England Journal of Medicine | 2018 | 187 |
| Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study | Lancet Oncology, The | 2018 | 134 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease | Blood | 2018 | 127 |
| Cancer immunotherapy beyond immune checkpoint inhibitors | Journal of Hematology and Oncology | 2018 | 126 |
| The multiple myelomas - current concepts in cytogenetic classification and therapy | Nature Reviews Clinical Oncology | 2018 | 121 |
| GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis | Leukemia | 2018 | 117 |
| Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management | American Journal of Hematology | 2018 | 115 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria | Blood Cancer Journal | 2018 | 115 |
| A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts | Lancet Oncology, The | 2018 | 112 |
| Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy | Frontiers in Immunology | 2018 | 112 |
| Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma | Nature Communications | 2018 | 103 |
| Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial | JAMA Oncology | 2018 | 101 |
| Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations | Acta Neuropathologica | 2018 | 99 |
| Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting | Blood Cancer Journal | 2018 | 97 |
| Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications | Blood | 2018 | 93 |
| A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy | Blood | 2018 | 90 |
| Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly | Cancer Cell | 2018 | 89 |
| The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy | Cell Systems | 2018 | 85 |
